Stefanie Schatz

504 total citations
13 papers, 50 citations indexed

About

Stefanie Schatz is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Stefanie Schatz has authored 13 papers receiving a total of 50 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Stefanie Schatz's work include Lung Cancer Treatments and Mutations (8 papers), Cancer Genomics and Diagnostics (4 papers) and Lung Cancer Diagnosis and Treatment (3 papers). Stefanie Schatz is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Cancer Genomics and Diagnostics (4 papers) and Lung Cancer Diagnosis and Treatment (3 papers). Stefanie Schatz collaborates with scholars based in Germany, Netherlands and Sweden. Stefanie Schatz's co-authors include Markus Tiemann, Frank Griesinger, Lukas C. Heukamp, Markus Falk, Linda Diehl, Claas Wesseler, Petra Hoffknecht, Stefanie Schmidt, Howard Safran and Thomas C. King and has published in prestigious journals such as Annals of Oncology, Cancers and Journal of Thoracic Oncology.

In The Last Decade

Stefanie Schatz

11 papers receiving 50 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stefanie Schatz Germany 5 38 31 14 10 9 13 50
Avanthi Tayi Shah United States 4 19 0.5× 19 0.6× 22 1.6× 7 0.7× 13 1.4× 11 50
Jana Krejčí Czechia 5 41 1.1× 41 1.3× 14 1.0× 4 0.4× 4 0.4× 17 62
Maciej Kawecki Poland 4 45 1.2× 17 0.5× 23 1.6× 19 1.9× 10 1.1× 7 65
Nilofer Azad United States 3 23 0.6× 30 1.0× 32 2.3× 10 1.0× 16 1.8× 4 58
Seunghun Han Saudi Arabia 2 18 0.5× 14 0.5× 19 1.4× 9 0.9× 19 2.1× 3 52
Á. Montesa Pino Spain 5 26 0.7× 14 0.5× 11 0.8× 5 0.5× 7 0.8× 12 48
Laura Monovich United States 3 53 1.4× 18 0.6× 33 2.4× 22 2.2× 18 2.0× 5 73
Rajesh Rawal Germany 3 19 0.5× 18 0.6× 10 0.7× 16 1.6× 12 1.3× 3 78
Émilie Angot France 4 15 0.4× 24 0.8× 17 1.2× 9 0.9× 18 2.0× 7 55
Tasha Lea United States 2 26 0.7× 18 0.6× 15 1.1× 3 0.3× 17 1.9× 2 47

Countries citing papers authored by Stefanie Schatz

Since Specialization
Citations

This map shows the geographic impact of Stefanie Schatz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefanie Schatz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefanie Schatz more than expected).

Fields of papers citing papers by Stefanie Schatz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefanie Schatz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefanie Schatz. The network helps show where Stefanie Schatz may publish in the future.

Co-authorship network of co-authors of Stefanie Schatz

This figure shows the co-authorship network connecting the top 25 collaborators of Stefanie Schatz. A scholar is included among the top collaborators of Stefanie Schatz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefanie Schatz. Stefanie Schatz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Falk, Markus, Stefanie Schatz, Markus Tiemann, Joachim H. Ficker, & Wolfgang M. Brueckl. (2025). KRAS under attack: recent advances in targeted therapies involving G12C inhibitors and XPO1 inhibition. Translational Lung Cancer Research. 14(10). 4184–4186.
2.
Falk, Markus, Stefanie Schmidt, Stefanie Schatz, et al.. (2023). Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy. Current Oncology. 30(2). 1692–1698. 6 indexed citations
3.
Falk, Markus, Stefanie Schatz, Stefanie Schmidt, et al.. (2023). Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report. Current Oncology. 30(10). 8865–8871. 1 indexed citations
4.
Falk, Markus, André Fehr, Andreas Stang, et al.. (2022). Outcome of Ordinary Polymorphous Adenocarcinomas of the Salivary Glands in Comparison With Papillary and Cribriform Subtypes. Anticancer Research. 42(3). 1455–1463.
5.
Falk, Markus, Lukas C. Heukamp, Stefanie Schatz, et al.. (2021). Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors. Pathology - Research and Practice. 227. 153651–153651. 2 indexed citations
6.
Schatz, Stefanie, Linda Diehl, Petra Hoffknecht, et al.. (2021). Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy. Cancers. 13(12). 2861–2861. 14 indexed citations
7.
Schatz, Stefanie, Markus Falk, Stefanie Schmidt, et al.. (2020). Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer. Cancers. 12(6). 1685–1685. 8 indexed citations
8.
Falk, Markus, Stefanie Schatz, Markus Tiemann, et al.. (2019). Treatment patterns of EGFR mt+ NSCLC IV pts: Real-world data of the NOWEL network. Annals of Oncology. 30. v630–v630. 1 indexed citations
9.
10.
Falk, Markus, Stefanie Schatz, Markus Tiemann, et al.. (2019). Risk of not receiving second-line therapy is high in EGFR mt+ patients: Real-world data of certified lung cancer centers on treatment sequence in EGFR mt+ patients. Annals of Oncology. 30. ii48–ii48. 1 indexed citations
11.
Falk, Martin, Stefanie Schatz, Markus Tiemann, et al.. (2018). P1.01-82 Risk of Not Receiving 2nd Line Therapy is High in EGFR mt+ pts: Real World Data of Certified Lung Cancer Centers on Treatment Sequence in EGFR mt+ pts. Journal of Thoracic Oncology. 13(10). S494–S495. 7 indexed citations
12.
Schatz, Stefanie, Markus Falk, Ranjeeta Menon, et al.. (2018). Hybrid capture NGS reliably detects a spectrum of clinically significant genetic aberrations in both, primary diagnostics and the relapse scenario. Annals of Oncology. 29. viii517–viii517. 1 indexed citations
13.
Young, Carolyn, Neil F. Gordon, Howard Safran, et al.. (1996). Monoclonal B-cell population mimicking lymphoma in a patient with multiple sclerosis.. PubMed. 120(3). 275–8. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Avanthi Tayi Shah Breakdown of academic impact, for papers by Jana Krejčí Breakdown of academic impact, for papers by Maciej Kawecki Breakdown of academic impact, for papers by Nilofer Azad Breakdown of academic impact, for papers by Seunghun Han Breakdown of academic impact, for papers by Á. Montesa Pino Breakdown of academic impact, for papers by Laura Monovich Breakdown of academic impact, for papers by Rajesh Rawal Breakdown of academic impact, for papers by Émilie Angot Breakdown of academic impact, for papers by Tasha Lea
Rankless by CCL
2026